Clinical Trial Update: Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bevacizumab with modified FOLFIRINOX for mucinous ovarian, fallopian tube, or primary peritoneal cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Mucinous Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Modified FOLFIRINOX (modified FOLFIRINOX)

Snippet

Sponsor: Yonsei University | Conditions: Mucinous Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: UNKNOWN